A Phase 1 interventional study of ONO-4538 in Malignant Solid Tumor, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-10-08.
Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect and efficacy of ONO-4538.
Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ONO-4538
1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
Cmax at Single Dose
Time frame: day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation
AUClast at Single Dose
Time frame: day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation
T1/2 at Single Dose
Time frame: day1(before administration, 1 hour after the start of administration, and 2 and 8 hours after the end of administration), day2(24 h), day3(48 h), day4(72 h), day8, day15, and day22 or at the discontinuation
Ceoi at Multiple Doses
Ceoi:Serum concentrations immediately after the end of continuous administration
Time frame: day 15
Best Overall Response
Response Evaluation Criteria In Solid Tumors Criteria (ver 1.0) was used for this Outcome Measure. Please see the reference for the detailed description. Therasse, Arbuck et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
Time frame: up to study completion, every 4 weeks in principle
| Milestone | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts |
|---|---|---|---|---|
| Started | 3 | 5 | 6 | 3 |
| Completed | 0 | 2 | 0 | 0 |
| Not completed | 3 | 3 | 6 | 3 |
| μg/mL | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts |
|---|---|---|---|---|
| Cmax at Single Dose | 24.4 ± 4.5 | 68.8 ± 10.9 | 192 ± 36 | 214 ± 68 |
| μg·h/mL | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts |
|---|---|---|---|---|
| AUClast at Single Dose | 4950 ± 580 | 12300 ± 4500 | 43900 ± 7200 | 67400 ± 15500 |
| day | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts |
|---|---|---|---|---|
| T1/2 at Single Dose | 15 ± 0 | 13 ± 7 | 21 ± 11 | 17 ± 9 |
Ceoi:Serum concentrations immediately after the end of continuous administration
| μg/mL | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts |
|---|---|---|---|---|
| Ceoi at Multiple Doses | 29.3 ± 6.0 | 101 ± 12 | 270 ± 42 | 286 ± 112 |
Response Evaluation Criteria In Solid Tumors Criteria (ver 1.0) was used for this Outcome Measure. Please see the reference for the detailed description. Therasse, Arbuck et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
| Participants | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts |
|---|---|---|---|---|
| CR | 0 | 1 | 0 | 0 |
| PR | 1 | 0 | 1 | 0 |
| SD | 0 | 1 | 2 | 0 |
| PD | 2 | 3 | 3 | 3 |
| Unknown | 0 | 0 | 0 | 0 |
Collected over All subjects treated with the study drug were followed up for at least 28 days after the last dose.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ONO-4538 1mg/kg Cohorts | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| ONO-4538 3mg/kg Cohorts | 0/5 (0%) | 1/5 (20%) | 5/5 (100%) |
| ONO-4538 10mg/kg Cohorts | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| ONO-4538 20mg/kg Cohorts | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts |
|---|---|---|---|---|
| pain in extremityMusculoskeletal and connective tissue disorders | 1/3 | 0/5 | 0/6 | 0/3 |
| malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/5 | 0/6 | 0/3 |
| dehydrationMetabolism and nutrition disorders | 0/3 | 0/5 | 1/6 | 0/3 |
| alanine aminotransferase increasedInvestigations | 0/3 | 0/5 | 1/6 | 0/3 |
| aspartate aminotransferase increasedInvestigations | 0/3 | 0/5 | 1/6 | 0/3 |
| blood bilirubin increasedInvestigations | 0/3 | 0/5 | 1/6 | 0/3 |
| Event | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts |
|---|---|---|---|---|
| Lymphocyte count decreasedInvestigations | 1/3 | 2/5 | 5/6 | 2/3 |
| NauseaGastrointestinal disorders | 0/3 | 1/5 | 1/6 | 2/3 |
| PyrexiaGeneral disorders | 1/3 | 1/5 | 2/6 | 2/3 |
| Blood albumin decreasedInvestigations | 1/3 | 3/5 | 2/6 | 2/3 |
| Blood creatine phosphokinase increasedInvestigations | 2/3 | 0/5 | 2/6 | 0/3 |
| C-reactive protein increasedInvestigations | 1/3 | 2/5 | 2/6 | 2/3 |
| Eosinophil count increasedInvestigations | 2/3 | 3/5 | 2/6 | 1/3 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 0/5 | 3/6 | 2/3 |
| DizzinessNervous system disorders | 0/3 | 1/5 | 0/6 | 2/3 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 0/3 | 0/5 | 0/6 | 2/3 |
| Age, Categorical(Participants) | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 4 | 5 | 1 | 11 |
| >=65 years | 2 | 1 | 1 | 2 | 6 |
| Sex: Female, Male(Participants) | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts | Total |
|---|---|---|---|---|---|
| Female | 1 | 5 | 0 | 1 | 7 |
| Male | 2 | 0 | 6 | 2 | 10 |
| Performance Status(ECOG)(Participants) | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts | Total |
|---|---|---|---|---|---|
| 0 | 1 | 1 | 2 | 0 | 4 |
| 1 | 2 | 4 | 4 | 3 | 13 |
| disease stage classification(Participants) | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts | Total |
|---|---|---|---|---|---|
| IV | 0 | 3 | 0 | 1 | 4 |
| IVb | 0 | 0 | 2 | 0 | 2 |
| Recurrent | 3 | 2 | 4 | 2 | 11 |
| Cancer treatment history (surgery)(Participants) | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts | Total |
|---|---|---|---|---|---|
| None | 0 | 1 | 2 | 2 | 5 |
| Present | 3 | 4 | 4 | 1 | 12 |
| Cancer treatment history (radiotherapy)(Participants) | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts | Total |
|---|---|---|---|---|---|
| None | 3 | 3 | 4 | 2 | 12 |
| Present | 0 | 2 | 2 | 1 | 5 |
| Cancer treatment history (drug therapy)(Participants) | ONO-4538 1mg/kg Cohorts | ONO-4538 3mg/kg Cohorts | ONO-4538 10mg/kg Cohorts | ONO-4538 20mg/kg Cohorts | Total |
|---|---|---|---|---|---|
| None | 0 | 0 | 1 | 0 | 1 |
| Present | 3 | 5 | 5 | 3 | 16 |
The record gives a start of Jan 2009 and a primary completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2020, 10 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab